Completed PHASE2 INTERVENTIONAL 1-arm NCT01267188

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

A Phase 2, Open-Label, Dose Titration Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Sponsor: Neurocrine Biosciences

Conditions Tardive Dyskinesia

Interventions NBI-98854

Updated 5 times since 2017 Last updated: Apr 18, 2011 Started: Jan 31, 2011 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Tardive Dyskinesia and is currently completed. Neurocrine Biosciences leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurocrine Biosciences

Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada